From GlobeNewswire: 2025-06-20 15:19:00

Lipella Pharmaceuticals Inc. (OTC: LIPO) has been delisted from The Nasdaq Capital Market due to violations of Listing Rules related to private placement transactions conducted between December 2024 and March 2025. The company’s common stock trading was suspended today. Despite the delisting, Lipella remains operationally sound and continues to advance its lead product candidates for various diseases. The company is exploring other markets to list its common stock and remains committed to relisting on a platform that provides liquidity and access for investors. CEO Dr. Jonathan Kaufman expressed disappointment but emphasized Lipella’s dedication to shareholders and clinical goals. Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing new drugs for diseases with unmet needs.



Read more at GlobeNewswire: Lipella Pharmaceuticals Announces Delisting from Nasdaq